Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring
TAEUS Liver demonstrates strong agreement with the industry’s imaging gold standard, MRI‑PDFF, across the full spectrum of steatotic liver disease and patient BMI
ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated...
ENDRA is converting static treasury assets into a dynamic rewards engine to support medical innovation
Company Officially Launches Digital Asset Treasury Strategy Focused on the Highest Conviction Holdings of Arca Investment Management to Enhance Long-Term Shareholder Value
Company Also Intends to Appoint Jeff Dorman to Digital Asset Advisory Board
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of T hermo- A coustic E nhanced U ltra S ound (TAEUS ® ...
ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that the company will report financial results for the three months ended...
ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announced today the closing of its previously announced underwritten...
ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announced today that it has priced an underwritten public offering...